---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-1"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-1. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 92 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence/rapide-1"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: RAPIDe-1

<a id="heading-3.1.2"></a>

## 3.1.2 RAPIDe-1

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Study aim in the publication

> “We aimed to investigate the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema attacks.”
> “The RAPIDe-1 phase 2 trial aimed to investigate whether oral deucrictibant, self-administered for on-demand treatment of hereditary angioedema attacks, would reduce attack severity, and also investigated the safety, tolerability and pharmacokinetics of deucrictibant.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.1-2"></a>

#### Registry brief summary

> “This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE).”
> “The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.1-3"></a>

#### Primary objective: symptom relief within 4 hours

> “Primary objective: to evaluate angioedema symptom relief within 4 hours in acute attacks of patients with HAE-1/2”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registry dates and number of locations

> “Study Start (Actual) 2021-02-03 Primary Completion (Actual) 2022-09-23 Study Completion (Actual) 2023-03-01”
> “This study has 36 locations”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.2-2"></a>

#### Sites, regions, and screening and randomization dates in the publication

> “Patients were recruited from 38 sites, including university hospitals and accredited angioedema centres, in North America, Europe, and Israel (appendix pp 2–4).”
> “Between Feb 3, 2021, and June 23, 2022, 89 patients were screened, of whom 74 were randomly assigned between Feb 23, 2021, and July 26, 2022 (figure 1).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.2-3"></a>

#### Countries and sites at topline, December 2022

> “December 8, 2022”
> “today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study”
> “Seventy-four patients were enrolled across 13 countries and were randomized into one of three single dose levels of PHVS416 and placebo.”
> “Pharvaris had previously announced the achievement of target enrollment across 33 sites in Canada, Europe, Israel, the UK, and the U.S.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.2-4"></a>

#### Sites reported in a March 2023 presentation

> “17-19 March 2023”
> “74 HAE patients enrolled from ~30 Sites in Canada, Europe, Israel, UK, and US”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.2-5"></a>

#### Trial start and topline timing

> “We commenced RAPIDe-1 in February 2021 and reported positive topline Phase 2 data in December 2022.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.2.2-6"></a>

#### U.S. clinical hold in August 2022 and partial lift for RAPIDe-1

> “In August 2022, the U.S. Food & Drug Administration (FDA) placed clinical studies of PHA121 in the U.S., including RAPIDe-1, on hold.”
> “Subsequent to the clinical holds, the company continues to evaluate PHVS416 for the treatment of acute attacks for continuing participants enrolled outside the U.S.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

> “In August 2022, the U.S. Food & Drug Administration (FDA) placed a hold on the clinical trials of PHA121 in the U.S. based on its review of nonclinical data. FDA has subsequently agreed to partially lift the clinical hold on RAPIDe-1 trial”
> “and allow 2 remaining U.S. participants in RAPIDe-1 to complete treatment of a final HAE attack per protocol.”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Two-part, randomized, double-blind, placebo-controlled, crossover, dose-ranging design

> “RAPIDe-1 was a double-blind, randomised, placebo-controlled, crossover, dose-ranging, 2-part phase 2 trial. Part 1 assessed the pharmacokinetics and safety of three doses of a deucrictibant immediate-release capsule (henceforth referred to as deucrictibant): 10 mg, 20 mg, and 30 mg. Part 2 assessed their efficacy and safety versus placebo in achieving hereditary angioedema attack symptom reduction and resolution.”
> “There were no protocol amendments affecting trial recruitment or conduct during the study.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.3-2"></a>

#### Randomization to dose cohorts and crossover treatment sequences

> “Participants were randomly assigned (1:1:1) to one of three groups receiving deucrictibant (10 mg, 20 mg, or 30 mg) and further to one of three crossover treatment sequences (deucrictibant–deucrictibant–placebo, deucrictibant–placebo–deucrictibant, or placebo–deucrictibant–deucrictibant; appendix, p 21).”
> “Randomisation of treatment sequence assignment was done by an interactive response technology (IRT) system. Randomisation was stratified by whether the patients was willing to participate in full pharmacokinetic sampling, which was planned for approximately four patients from each dose cohort during an attack-free period in Part 1.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “From Part I to Part II, participants remained at their randomly assigned dose level.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.3-3"></a>

#### Masking and identical capsules

> “Participants, investigators, site personnel, and the sponsor were masked to treatment assignment. Capsules of deucrictibant and placebo were identical and each single dose consisted of a combination of three capsules of deucrictibant or placebo in a wallet.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.3-4"></a>

#### Registry design details

> “Allocation : Randomized”
> “Interventional Model : Crossover Assignment”
> “Masking : Quadruple”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.3-5"></a>

#### Investigator confirmation of each attack by remote consultation

> “Qualification of attacks for treatment with study drug had to be confirmed the Investigator or designee before administration of study drug via a remote consultation.”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="topic-3.1.2.3-6"></a>

#### Safety visits, end-of-trial visit, and electronic attack diary

> “For qualifying attacks, patients recorded attack information via an electronic data capture device from attack onset to study drug administration and up to 48 h thereafter.”
> “Safety visits occurred up to and including 5 days from each treated attack, and an end-of-trial visit occurred 10 (± 5) days after the last attack or at trial withdrawal.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.3-7"></a>

#### Rollover to CHAPTER-1 or RAPIDe-2 after the trial

> “Following treatment of participation in RAPIDe-1, participants were eligible to either join the Phase 2 randomized clinical trial of deucrictibant for the prevention of HAE attacks (CHAPTER-1) or roll over to the long-term extension on-demand study (RAPIDe-2).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion criteria in the publication: age, HAE type, and attack frequency

> “Adults aged 18–75 years with hereditary angioedema type 1 or 2, who had experienced two or more attacks within the past 2 months or three or more attacks within the past 4 months before screening were eligible for inclusion.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.4-2"></a>

#### Long-term prophylaxis exclusion and washout periods

> “Patients receiving long-term prophylactic therapy for hereditary angioedema at screening were not eligible. Patients who had previously discontinued long-term prophylaxis because of intolerance or lack of efficacy could enter the study provided that they had not been exposed to a C1 inhibitor, berotralstat, attenuated androgens, or anti-fibrinolytics at least 2 weeks before screening, and to lanadelumab 12 weeks before screening.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Use of HAE therapies prior to enrolment: C1-inhibitor (C1-INH) for acute use or short-term prophylaxis (7 days); C1-INH for prophylaxis, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics (2 weeks); monoclonal antibodies for HAE therapy (12 weeks);”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="topic-3.1.2.4-3"></a>

#### Hepatic and renal function, CYP3A4 inhibitors or inducers, and pregnancy

> “Patients were excluded in cases of abnormal hepatic or renal function, or if they were receiving moderate or potent CYP3A4 inhibitors or inducers. As reproductive and developmental toxicity studies were not available for deucrictibant and potential effects of deucrictibant on the fetus were unknown, pregnant and breastfeeding women were not eligible.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.4-4"></a>

#### Registry key inclusion and exclusion criteria

> “Documented history of HAE attacks: at least three in the last 4 months, or at least two in the last 2 months prior to screening”
> “Reliable access and experience to use standard of care acute attack medications”
> “Clinically significant abnormal electrocardiogram”
> “Positive serology for HIV or active infection with hepatitis B virus or hepatitis C virus”
> “History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse”
> “18 Years to 75 Years”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.4-5"></a>

#### Attack-level criteria: qualifying and excluded attacks

> “Attacks with any symptoms involving the internal head or neck, including laryngeal attacks, or presenting with vomiting, did not qualify for study drug treatment and patients were instructed to immediately treat with standard on-demand medication. Attacks involving the face or neck with cutaneous manifestations were eligible for study drug treatment. Attacks occurring less than 5 days after a previously treated attack were also excluded.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Part 1 single dose in the attack-free state and Part 2 home self-administration

> “During Part 1, patients in a non-attack state received the assigned single dose of deucrictibant at the trial site to assess safety. Selected patients underwent plasma sampling before and after the single dose for pharmacokinetic assessments. In Part 2, patients were instructed to self-administer deucrictibant at home in the assigned treatment sequence to treat three investigator-confirmed qualifying attacks within 3 h after at least one symptom (skin pain, skin swelling, or abdominal pain) reached a visual analog scale (VAS) individual score of at least 30 out of 100 and within 6 h from symptom onset.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.5-2"></a>

#### Doses and crossover sequences per dose cohort

> “In Part I, participants in a quiescent state received a single dose of PHA-022121 at the assigned dose (10, 20, or 30 mg) to assess PK and safety. In Part II, participants received 2 single doses of PHA-022121 (10, 20, or 30 mg) and one single dose of placebo to assess efficacy and safety. Each participant administered their randomly assigned dose (either 10, 20, or 30 mg) for each of the 3 qualifying HAE attacks according to 1 of the 3 randomly assigned treatment sequences (crossover design).”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.5-3"></a>

#### Registry interventions: soft capsules and matching placebo

> “deucrictibant soft capsules for oral use”
> “PHA-022121 PHA121 PHVS416”
> “Matching placebo capsules for oral use”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.5-4"></a>

#### Formulation: PHVS416 softgel capsule

> “PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.5-5"></a>

#### Rescue medication permitted from 4 hours after study drug

> “At 4 h or more after study drug administration, conventional on-demand therapy as rescue medication was allowed in case of insufficient symptom relief.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.5-6"></a>

#### Dose selection based on the bradykinin challenge and EC85

> “EC85 levels were established as threshold for therapeutic exposure using bradykinin challenge, a human in vivo surrogate-marker study in healthy volunteers”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

> “From the bradykinin challenge model, we were able to predict the efficacious dose range and the duration of effect of a single oral dose of deucrictibant; the topline data from our Phase 2 RAPIDe-1 trial treating HAE attacks were consistent with the predictions of the bradykinin challenge in both onset of symptom relief and duration of effect (use of rescue medication).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Change in the 3-Symptom Composite Visual Analogue Scale Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint: definition and assessment schedule in the publication

> “The primary efficacy endpoint was change in the patient-reported composite VAS score (VAS-3)”
> “The VAS-3 was calculated as the mean of three individual VAS scores assessing the three major hereditary angioedema symptoms: skin swelling, skin pain, and abdominal pain. Each symptom was rated separately on a 0–100 scale, where 0 indicated no swelling (for skin swelling) or no pain (for skin and abdominal pain), and 100 indicated extreme swelling or extreme pain, respectively. Scores were recorded before treatment, every 30 min (± 10) up to 4 h, and at 5 h (± 0·5), 6 h (± 0·5), 8 h (± 1), 24 h (± 4), and 48 h (± 6) post-treatment thereafter.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-2"></a>

##### Primary endpoint: registry definition

> “The primary endpoint of the study was the change of the VAS-3 (3-symptom composite visual analogue scale) score from pre-treatment to 4 hours post-treatment. The VAS-3 was calculated as the mean of the VAS scores of the 3 major HAE symptoms: skin swelling, skin pain, and abdominal pain. The VAS scores of the 3 major HAE symptoms (skin swelling, skin pain, and abdominal pain) could range between 0 (No swelling/No pain) and 100 (Extreme swelling/Excruciating pain)”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.6.1-3"></a>

##### Electronic, numerically assisted capture of the VAS-3

> “The primary endpoint of the study (Table 1) is the change of a three-symptom composite (skin pain, skin swelling, abdominal pain) visual analogue scale (VAS-3) score from pre-treatment to four hours post-treatment, as captured electronically using numerically assisted input.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.6.1-4"></a>

##### Authors' rationale: 4-hour timepoint and scales used in earlier on-demand trials

> “Change was evaluated at 4 h as in other previous on-demand trials in hereditary angioedema.”
> “The scales and outcomes used in this trial were validated for hereditary angioedema and previously used in randomised controlled trials for on-demand treatment.”
> “In a trial of subcutaneous icatibant,”
> “the difference in mean VAS-3 score 4 h after treatment with icatibant and placebo was similar to that between deucrictibant and placebo in RAPIDe-1.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-5"></a>

##### Sponsor rationale: VAS in icatibant and recombinant C1 esterase inhibitor approvals and the FDA outcome assessment compendium

> “VAS-3 is a measure of HAE attack severity based on electronically-captured numerically-assisted visual scale”
> “Used in approval of two most recently approved on-demand therapies”
> “Icatibant and recombinant C1 esterase inhibitor”
> “VAS, MSCS, TOS are only endpoints listed for attacks in FDA compendium of clinical outcome assessments (2021) as listed by Division of Pulmonology, Allergy and Critical Care”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.6.1-6"></a>

##### Three-symptom VAS in the icatibant FAST-1 and FAST-2 trials

> “Patients presenting with cutaneous or abdominal attacks were asked to evaluate the severity of three specific symptoms (cutaneous swelling, cutaneous pain, and abdominal pain) on a visual-analogue scale.”
> “A composite score on the visual-analogue scale was calculated by taking the average of the three scores for the main symptoms”
> “and defining symptom relief as a 50% reduction from the baseline score.”
> “On the basis of the composite scores, the median time to symptom relief was 2.5 hours with icatibant versus 7.0 hours with placebo (P = 0.02) in FAST-1 and 2.0 hours with icatibant versus 15.0 hours with tranexamic acid (P<0.001) in FAST-2”

Source: [Cicardi et al. (2010a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4662377/)

<a id="topic-3.1.2.6.1-7"></a>

##### Content validity of HAE VAS instruments

> “It demonstrated the content validity of the four anatomical location HAE VAS instruments and their suitability for use in clinical trials of recombinant human C1INH (rhC1INH) treatment for ascertaining trial participants' assessments of the severity of acute angioedema symptoms.”

Source: [McMillan et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22462765/)

<a id="topic-3.1.2.6.1-8"></a>

##### VAS-3 in earlier on-demand trials and its adaptation to electronic AMRA instruments

> “The visual analog scale 3-symptom (VAS-3) and 5-symptom (VAS-5) are PROs that have also been used in earlier clinical trials of ODTs for HAE to derive key endpoints for clinical outcomes, such as a ≥30% or ≥50% reduction in symptom severity”
> “However, VAS-3 and VAS-5 were adapted into electronic assessments and renamed AMRA-3 (used for non-upper-airway attacks) and AMRA-5 (used for upper-airway attacks, including laryngeal attacks) and, therefore, require content validation and assessment of their psychometric properties in the HAE population”

Source: [Mendivil et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12953491/)

<a id="topic-3.1.2.6.1-9"></a>

##### Key secondary endpoints: time-to-event VAS-3 outcomes, MSCS, and TOS

> “Key secondary efficacy endpoints were time to symptom relief onset (≥30% reduction in VAS-3 score from pre-treatment), time to 50% or greater reduction in VAS-3 score, and time to almost complete or complete symptom resolution (all individual VAS scores ≤10 for two consecutive assessments), along with change in mean symptom complex severity (MSCS) score from pre-treatment to 4 h post-treatment, and treatment outcome score (TOS) at 4 h post-treatment.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-10"></a>

##### Key secondary endpoint: registry definition of almost complete or complete symptom relief

> “Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value < 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0.”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.6.1-11"></a>

##### Key secondary endpoints: MSCS and TOS instruments

> “Mean Symptom Complex Severity (MSCS) score and Treatment Outcome Score (TOS) are validated composite scores based on patient-reported symptoms of attacks at the affected body sites, included in ecallantide clinical trials”
> “MSCS is a point-in-time measure of symptom severity”
> “Patient-rated severity of each affected symptom on a categorical scale (0 = normal, 1 = mild, 2 = moderate, 3 = severe)”
> “TOS is a measure of symptom response to treatment”
> “Patient assessment of response for each affected body site on categorical scale (significant improvement [100], improvement [50], same [0], worsening [-50], significant worsening [-100])”

Source: [Riedl et al. (2023b)](https://ir.pharvaris.com/static-files/1d0c218c-12ee-4a4e-93bc-b9c939dac963)

<a id="topic-3.1.2.6.1-12"></a>

##### Key secondary endpoints: validation and minimally important differences of TOS and MSCS

> “Anchor- and distribution-based analyses suggested that conservative estimates for MID are 30 points for TOS and -0.30 points for 4-h change in MSCS score.”
> “The psychometric tests performed here provide evidence of the reliability and validity of the TOS and MSCS for evaluating symptom severity and change in HAE patients.”

Source: [Vernon et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19597964/)

<a id="topic-3.1.2.6.1-13"></a>

##### Other secondary endpoints: rescue medication use and lower-ranked endpoints including TSQM

> “Rescue medication use was an additional secondary outcome and was assessed as the proportion of study drug-treated attacks with conventional therapy within 12 h, 24 h, and 48 h post-treatment and time to first rescue medication use. Time to 30% or greater and 50% or greater reduction in VAS for the primary symptom, change in the VAS score for individual symptoms from pre-treatment to 4 h, change in MSCS score from pre-treatment to 24 h post-treatment, TOS at 24 h post-treatment, and Treatment Satisfaction Questionnaire for Medication (TSQM) score, were other lower-ranked secondary endpoints and will be reported elsewhere.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-14"></a>

##### Other secondary endpoint: TSQM registry definition

> “The 11-item TSQM (version II) evaluated participant treatment satisfaction with the medication for the following scales: effectiveness, side effects, convenience, and overall satisfaction Scale scores were transformed into scores ranging from 0 to 100 and could be used to calculate a total composite score, a higher score indicating greater satisfaction.”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

<a id="topic-3.1.2.6.1-15"></a>

##### Safety endpoints

> “Safety endpoints were adverse events occurring within 5 days of treatment. Adverse event reporting information collected included time of onset, severity, relationship to study drug, action taken, outcome, and date of resolution. Additionally, pharmacokinetics was investigated for all doses.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.6.1-16"></a>

##### Post hoc endpoint: time to end of progression

> “A recent consensus study established EoP as a key core outcome score that should be measured and reported in all clinical trials for on-demand treatment of HAE”
> “A post-hoc analysis was conducted to assess time to EoP of HAE attack manifestations in the RAPIDe-1 trial.”
> “Time to EoP was defined as the earliest post-treatment timepoint with the highest 3-symptom composite (skin pain, skin swelling, abdominal pain) visual analogue scale (VAS-3) score with no use of rescue medication.”

Source: [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9)

Additional sources: [Lumry et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22123383/)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Sample size and power assumptions

> “Based on previous trials”
> “and assuming a treatment effect difference of 10 points (with an SD of 11) in VAS-3 score change from pre-treatment to 4 h post-treatment between deucrictibant (20 mg or 30 mg) and placebo, 72 randomly assigned patients were expected to provide 90% power to test the primary endpoint at a significance level of 2·5% for a two-sided test, accounting for attrition in evaluable attacks and possible rescue medication use.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.1-2"></a>

##### Registry enrollment and participants randomized per dose cohort

> “Enrollment (Actual) 74”

Source: [ClinicalTrials.gov NCT04618211](https://clinicaltrials.gov/study/NCT04618211)

> “A total of 89 patients were screened, of which 74 patients were enrolled and randomized to the 3 PHA-022121 cohorts as follows: 25 participants to the 30 mg cohort, 25 participants to the 20 mg cohort, and 24 participants to the 10 mg cohort.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants and attacks in the primary efficacy analysis

> “The primary efficacy analysis included 147 attacks in 62 patients, of whom 42 (68%) were female and 60 (97%) were White.”
> “Of the 147 study drug-treated attacks, 37 (25%) were in 21 patients treated with deucrictibant 10 mg, 28 (19%) were in 16 patients treated with deucrictibant 20 mg, 31 (21%) were in 20 patients treated with deucrictibant 30 mg, and 51 (35%) were in 51 patients treated with placebo (table 2).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants and attacks in the safety analysis set

> “In Part 1, eight (11%) of 72 patients in the safety analysis set reported treatment-emergent adverse events within 5 days post-treatment”
> “In Part 2, the safety analysis set included 156 attacks treated with deucrictibant 10 mg, 20 mg, 30 mg, or placebo.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “156 attacks from 73 patients were included in the Safety Analysis Set”
> “147 attacks from 62 patients were included in the mITT Analysis Set for efficacy”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.7.1-5"></a>

##### Attacks in the final analysis and participants with pharmacokinetic sampling

> “The final analysis included 165 attacks, with nine additional attacks that occurred after data cutoff for the primary analysis.”
> “Pharmacokinetics were assessed in samples collected from 12 patients during Part 1.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Full analysis set

> “The primary analysis (full analysis set) comprised all patients enrolled and randomly assigned in the study.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “The FAS was defined as all participants enrolled and randomized in the study. Participants were analyzed based on the intention-to-treat principle, i.e., according to their randomized treatment assignment regardless of actual treatment taken.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.7.2-2"></a>

##### Modified intention-to-treat and per-protocol analysis sets

> “The primary endpoint and key secondary endpoints were analysed in the modified intention-to-treat (mITT) analysis set (defined as patients with ≥1 study drug-treated attack and VAS-3 data at pre-treatment and ≥1 post-treatment timepoints) and also repeated with the per-protocol analysis set (defined as a subset of the mITT analysis set, comprising all patients who had at least one attack satisfying mITT analysis set criteria, and who also had no major protocol deviations or other non-compliance that could affect the key efficacy assessment) as a prespecified supplementary analysis.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-3"></a>

##### Safety and pharmacokinetic analysis sets

> “The safety analysis set comprised all patients who received at least one dose of study drug, and analyses were summarised by dose. Pharmacokinetic analyses were conducted for patients who received at least one dose of study drug and had at least one measurable concentration of deucrictibant in Part 1.”
> “In part 1, adverse event data are provided as frequencies and percentages of patients. In part 2, adverse event data are provided as frequencies and percentages of attacks with adverse events as well as frequencies and percentages of patients.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-4"></a>

##### Primary analysis before all participants had three attacks, and descriptive final analysis

> “The primary analysis, planned as a formal analysis in the trial protocol to assess the objectives of this study, was done before all enrolled patients had three qualifying attacks. A final analysis was subsequently conducted on data collected through to the end of the trial for descriptive purposes.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-5"></a>

##### Primary endpoint model: mixed model for repeated measures

> “A mixed model for repeated measures (MMRM) was used to estimate the least squares mean difference in VAS-3 score change from pre-treatment to 4 h post-treatment between each deucrictibant dose and placebo.”
> “The MMRM included treatment, time, treatment-by-time interaction, as well as attack as fixed effects, patient as a random effect, and attack specific pre-treatment VAS-3 value as a covariate. A heterogeneous Toeplitz covariance structure was assumed. VAS-3 results after the intake of rescue medication or prohibited medication were set to missing.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-6"></a>

##### Prespecified sensitivity analyses of the primary endpoint

> “For the primary endpoint, a prespecified sensitivity analysis was done with the missing not at random (MNAR) assumption. VAS-3 results after the intake of hereditary angioedema rescue medication or prohibited medications were set to missing and handled with control-based multiple imputation. Other prespecified sensitivity analyses, such as an analysis using only the first treated attack of each patient, and an analysis excluding data with inconsistent reporting between VAS and MSCS or TOS, were also done to assess the robustness of the primary conclusions.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-7"></a>

##### Multiplicity control for the 20 mg and 30 mg branches, and descriptive 10 mg analyses

> “Initially, the full α=0·05 was split equally (α=0·025) and allocated to two branches corresponding to the hypotheses for deucrictibant 20 mg versus placebo and deucrictibant 30 mg versus placebo. Within each branch, endpoints were tested sequentially: the primary endpoint first, followed by the key secondary endpoints in the prespecified hierarchical order.”
> “The 10 mg group was included to evaluate dose–response without multiplicity control procedures, and analyses were therefore descriptive.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “The statistical tests for the primary and all key secondary endpoints followed a pre-specified multiple comparison procedure to assess statistical significance for PHVS416 20 mg and 30 mg, supported by a nominal statistical analysis for PHVS416 10 mg.”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.7.2-8"></a>

##### Time-to-event and rescue medication analyses

> “Time-to-event endpoints were summarised with the Kaplan–Meier method, and treatment effect was estimated by use of marginal Cox proportional hazards models with robust variance-covariance estimator to account for within-patient correlation. For attacks not achieving the outcome of interest at predefined timepoints, the time was censored at the last recorded assessment. For attacks with rescue medication or prohibited medication use, time was censored at the last assessment recorded before rescue medication or prohibited medication.”
> “For the evaluation of rescue medication use, odds ratios with 95% CIs and p values were estimated with a generalised estimating equation model with a logit link, adjusting for treatment, attack, and pre-treatment VAS-3 value, with an identity matrix specified as the working correlation structure.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.7.2-9"></a>

##### Registry caveat on Kaplan-Meier medians

> “the within participant correlation was not accounted for in the Kaplan-Meier estimation of median time and corresponding 95% confidence interval.”
> “Participant flow is reported according to randomized treatment cohort, efficacy”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Screening, randomization, and follow-up in the primary analysis set

> “Between Feb 3, 2021, and June 23, 2022, 89 patients were screened, of whom 74 were randomly assigned between Feb 23, 2021, and July 26, 2022 (figure 1). For the primary analysis set, the median follow-up was 130·0 (IQR 92·5–212·5) days for deucrictibant 10 mg, 166·5 (80·0–275·0) days for deucrictibant 20 mg, and 172·0 (65·0–242·0) days for deucrictibant 30 mg. Similar numbers of patients across the groups completed Part 1, treated one, two, or three attacks in Part 2, and completed post-attack visits before the primary analysis cutoff (figure 1).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.1-2"></a>

##### Registry participant flow by randomized dose cohort, Part I and Part II

| Milestone | Deucrictibant 10 mg cohort | Deucrictibant 20 mg cohort | Deucrictibant 30 mg cohort |
| --- | --- | --- | --- |
| Part I started | “24” | “25” | “25” |
| Part I completed | “24” | “24” | “25” |
| Part I withdrawal by subject | “0” | “1” | “0” |
| Part II started | “24” | “24” | “25” |
| Part II completed | “16” | “12” | “12” |
| Part II not completed | “8” | “12” | “13” |
| Part II withdrawal by subject | “2” | “3” | “5” |
| Part II not completed: “Participants Met Primary Analysis Criteria” | “6” | “9” | “8” |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Participant flow is reported according to randomized treatment cohort”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.1-3"></a>

##### Follow-up in the final analysis

> “The median follow-up was 130·0 days (IQR 92·5–249·0) for deucrictibant 10 mg, 190·5 days (94·0–384·5) for deucrictibant 20 mg, and 174·0 days (65·0–330·0) for deucrictibant 30 mg.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Demographics and HAE characteristics by dose cohort, full analysis set

| Characteristic | Deucrictibant 10 mg (n=24) | Deucrictibant 20 mg (n=25) | Deucrictibant 30 mg (n=25) |
| --- | --- | --- | --- |
| Age, years, median (IQR) | “44 (31–53)” | “45 (36–57)” | “39 (25–53)” |
| Female, n (%) | “17 (71%)” | “17 (68%)” | “15 (60%)” |
| White, n (%) | “22 (92%)” | “24 (96%)” | “25 (100%)” |
| HAE-C1INH type 1, n (%) | “19 (79%)” | “22 (88%)” | “24 (96%)” |
| HAE-C1INH type 2, n (%) | “5 (21%)” | “2 (8%)” | “1 (4%)” |
| Time since diagnosis, years, median (IQR) | “18 (10–26)” | “21 (13–37)” | “23 (10–37)” |
| More than 4 attacks in the 4 months before screening, n (%) | “20 (83%)” | “20 (80%)” | “20 (80%)” |
| Long-term prophylactic treatment history, n (%) | “3 (13%)” | “5 (20%)” | “5 (20%)” |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Demographics and baseline clinical characteristics of the full analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.2-2"></a>

##### Attack frequency and prior HAE medication, full analysis set

> “Demographics and baseline characteristics, including hereditary angioedema-related medical history, were balanced across groups and similar to those in another recent trial of on-demand treatment (table 1; appendix pp 7–8).”
> “Of 74 patients, 68 (92%) had experienced four or more attacks in the 4 months before screening. Previous use of hereditary angioedema medication (primarily icatibant and a C1 inhibitor) was reported for 70 (95%) of 74 patients; 13 (18%) patients reported previous long-term prophylaxis use.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.2-3"></a>

##### Registry baseline age and ethnicity, full analysis set

| Characteristic | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Total |
| --- | --- | --- | --- | --- |
| Participants | “24” | “25” | “25” | “74” |
| Age, years, mean (SD) | “42.9” (“14.15”) | “45.7” (“13.89”) | “41.4” (“15.38”) | “43.3” (“14.41”) |
| Aged 65 to 84 years | “2” | “1” | “2” | “5” |
| Hispanic or Latino | “3” | “2” | “0” | “5” |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Full Analysis Set (FAS): The FAS was defined as all participants enrolled and randomized in the study.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.2-4"></a>

##### Sex and race, mITT analysis set of 62 participants

> “The mITT analysis set for the primary analysis comprised 62 patients, of whom 42 (68%) were female and 60 (97%) were White (appendix pp 7–8).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.2-5"></a>

##### Pre-treatment VAS-3 scores of treated attacks, mITT analysis set

| Treatment of the attack | Attacks | Pre-treatment VAS-3, mean (SD) |
| --- | --- | --- |
| Deucrictibant 10 mg | “37” | “26·16 (11·67)” |
| Deucrictibant 20 mg | “28” | “25·46 (10·00)” |
| Deucrictibant 30 mg | “31” | “29·73 (13·53)” |
| Placebo | “51” | “27·76 (11·25)” |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Median VAS-3 at pre-treatment ranged from 24.33 to 27.00 across different dose levels”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary endpoint: change in VAS-3 at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set of 147 attacks in 62 participants

| Measure | Deucrictibant 10 mg (n=21) | Deucrictibant 20 mg (n=16) | Deucrictibant 30 mg (n=20) | Placebo (n=51) |
| --- | --- | --- | --- | --- |
| Attacks with VAS-3 at 4 h | “33” | “27” | “30” | “43” |
| VAS-3 at 4 h, mean (SD) | “12·09 (14·47)” | “11·93 (9·97)” | “14·71 (10·51)” | “30·09 (18·20)” |
| LSM difference vs placebo (95% CI) | “−16·75 (−21·52 to −11·97)” | “−15·02 (−20·22 to −9·81)” | “−16·28 (−21·27 to −11·29)” | Not applicable |
| p value | Not reported | “<0·0001” | “<0·0001” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”
> “The primary efficacy analysis included 147 attacks in 62 patients”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Deucrictibant 20 mg and 30 mg significantly reduced the severity of attack symptoms, measured as a change in VAS-3 score at 4 h post-treatment versus placebo; the least squares mean difference was –15·02 (95% CI –20·22 to –9·81) for 20 mg and –16·28 (–21·27 to –11·29) for 30 mg (p<0·0001 for both; figure 2A; table 2). For the 10 mg treatment group, the least squares mean difference was –16·75 (95% CI –21·52 to –11·97).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary endpoint: registry least squares mean change and nominal p value for 10 mg, participants with evaluable data

| Group | Participants | LS mean change in VAS-3 (SE) | LS mean difference vs placebo (95% CI) | p value |
| --- | --- | --- | --- | --- |
| Deucrictibant 10 mg | “21” | “-14.83” (“1.833”) | “-16.75” (“-21.52” to “-11.97”) | “< 0.0001”, “Nominal p-value” |
| Deucrictibant 20 mg | “16” | “-13.10” (“2.111”) | “-15.02” (“-20.22” to “-9.81”) | “< 0.0001” |
| Deucrictibant 30 mg | “20” | “-14.37” (“1.975”) | “-16.28” (“-21.27” to “-11.29”) | “< 0.0001” |
| Placebo | “51” | “1.92” (“1.596”) | Not applicable | Not applicable |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Part I efficacy data not collected, consistent with and pre-specified in the study protocol. Includes all participants with evaluable data who completed the relevant assessment time point.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.3-3"></a>

##### Primary endpoint: sensitivity analyses and VAS-3 course over time

> “Prespecified sensitivity and supplementary analyses yielded results consistent with those of the primary statistical analysis, supporting the robustness of the primary findings (appendix pp 9–10). At each timepoint from 1–24 h post-treatment, mean VAS-3 score decreased for deucrictibant-treated attacks, whereas it remained stable for placebo-treated attacks until declining at 4 h, primarily due to censoring at use of rescue medication (appendix p 22).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-4"></a>

##### Primary endpoint: post hoc pooled deucrictibant doses versus placebo

> “Combined PHVS416 -16.08 (-19.87, -12.29)”
> “The Combined PHVS416 results are based on post-hoc analysis using a similar MMRM with all three active doses combined vs placebo.”

Source: [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

<a id="topic-3.1.2.8.3-5"></a>

##### Key secondary endpoints: multiplicity-controlled results for 20 mg and 30 mg

> “In the efficacy evaluation, following the planned multiplicity control procedure for testing the primary and key secondary endpoints, all the hypotheses in each branch (20 mg and 30 mg) were successfully rejected at the allocated α=0·025.”
> “Statistical significance was achieved in treatment effect compared to placebo for the primary endpoint and all key secondary endpoints for both 20 mg and 30 mg.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-6"></a>

##### Key secondary endpoints: time to symptom relief, 50% reduction, and resolution by VAS-3, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set

| Endpoint and measure | Deucrictibant 10 mg (37 attacks) | Deucrictibant 20 mg (28 attacks) | Deucrictibant 30 mg (31 attacks) | Placebo (51 attacks) |
| --- | --- | --- | --- | --- |
| Onset of symptom relief (≥30% VAS-3 reduction), median h (95% CI) | “2·1 (1·5 to 2·9)” | “2·7 (1·9 to 3·5)” | “2·5 (1·9 to 3·8)” | “8·0 (7·6 to NE)” |
| Onset of symptom relief, hazard ratio (95% CI) | “3·81 (2·01 to 7·20)” | “3·08 (1·50 to 6·30)” | “3·61 (2·10 to 6·19)” | Not applicable |
| Onset of symptom relief, p value | Not reported | “0·0021” | “<0·0001” | Not applicable |
| ≥50% VAS-3 reduction, median h (95% CI) | “3·3 (2·4 to 3·9)” | “4·0 (2·9 to 6·0)” | “4·0 (3·3 to 5·8)” | “22·8 (20·0 to 24·1)” |
| ≥50% VAS-3 reduction, hazard ratio (95% CI) | “4·55 (2·41 to 8·59)” | “3·65 (1·80 to 7·38)” | “3·87 (2·26 to 6·63)” | Not applicable |
| ≥50% VAS-3 reduction, p value | Not reported | “0·0003” | “<0·0001” | Not applicable |
| Almost complete or complete symptom relief, median h (95% CI) | “5·8 (3·6 to 7·5)” | “20·0 (4·5 to 20·0)” | “20·0 (6·0 to 20·1)” | “42·0 (22·0 to NE)” |
| Almost complete or complete symptom relief, hazard ratio (95% CI) | “5·09 (2·81 to 9·22)” | “2·25 (1·19 to 4·27)” | “2·65 (1·61 to 4·38)” | Not applicable |
| Almost complete or complete symptom relief, p value | Not reported | “0·013” | “<0·0001” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-7"></a>

##### Key secondary endpoints: change in MSCS score and TOS at 4 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set

| Endpoint and measure | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Placebo |
| --- | --- | --- | --- | --- |
| MSCS, attacks | “32” | “26” | “27” | “40” |
| MSCS, mean change from pre-treatment (SD) | “−1·08 (0·13)” | “−0·91 (0·14)” | “−0·68 (0·14)” | “−0·29 (0·11)” |
| MSCS, LSM difference vs placebo (95% CI) | “−0·79 (−1·11 to −0·46)” | “−0·61 (−0·97 to −0·26)” | “−0·39 (−0·73 to −0·04)” | Not applicable |
| MSCS, p value | Not reported | “0·0008” | “0·029” | Not applicable |
| TOS, attacks | “32” | “25” | “28” | “40” |
| TOS, mean (SD) score | “57·03 (58·63)” | “62·67 (36·09)” | “68·75 (38·86)” | “−2·71 (62·49)” |
| TOS, LSM difference vs placebo (95% CI) | “64·13 (40·35 to 87·91)” | “62·69 (36·71 to 88·67)” | “71·06 (46·09 to 96·03)” | Not applicable |
| TOS, p value | Not reported | “<0·0001” | “<0·0001” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Changes greater than the minimal clinically important differences in MSCS score (–0·30) and mean TOS (30) were observed for deucrictibant-treated attacks at 4 h, but not for placebo-treated attacks (table 2; appendix p 23).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-8"></a>

##### Symptom resolution within 24 hours without rescue medication, deucrictibant 20 and 30 mg versus placebo

> “The proportion of attacks with almost complete or complete symptom resolution within 24 h without rescue medication use was 71% (20 of 28) for deucrictibant 20 mg, 74% (23 of 31) for deucrictibant 30 mg, and 16% (eight of 51) for placebo (appendix p 12).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-9"></a>

##### Rescue medication use within 12, 24, and 48 hours, deucrictibant 10, 20, and 30 mg versus placebo, mITT analysis set

| Window and measure | Deucrictibant 10 mg | Deucrictibant 20 mg | Deucrictibant 30 mg | Placebo |
| --- | --- | --- | --- | --- |
| Within 12 h, attacks with rescue medication, n (%) | “7 (19%)” | “3 (11%)” | “2 (7%)” | “31 (61%)” |
| Within 12 h, OR vs placebo (95% CI) | “0·15 (0·06 to 0·37)” | “0·08 (0·02 to 0·35)” | “0·04 (0·01 to 0·18)” | Not applicable |
| Within 24 h, attacks with rescue medication, n (%) | “9 (24%)” | “3 (11%)” | “4 (13%)” | “37 (73%)” |
| Within 24 h, OR vs placebo (95% CI) | “0·12 (0·05 to 0·29)” | “0·05 (0·01 to 0·19)” | “0·06 (0·02 to 0·18)” | Not applicable |
| Within 48 h, attacks with rescue medication, n (%) | “9 (24%)” | “4 (14%)” | “5 (16%)” | “37 (73%)” |
| Within 48 h, OR vs placebo (95% CI) | “0·12 (0·05 to 0·29)” | “0·07 (0·02 to 0·24)” | “0·07 (0·02 to 0·22)” | Not applicable |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Primary and secondary endpoints in the modified intention-to-treat analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “A lower proportion of deucrictibant-treated versus placebo-treated attacks used rescue medication within 12 h, 24 h, and 48 h (table 2; figure 3A) and the median time to first rescue medication use was non-evaluable following deucrictibant treatment and 6·0 h (95% CI 4·4 to 13·1) following placebo treatment (figure 3B). Rescue medications used were icatibant, plasma-derived C1 inhibitor, and recombinant human C1 inhibitor.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-10"></a>

##### Rescue medication use in the top-line data, December 2022, deucrictibant 10, 20, and 30 mg versus placebo

> “December 8, 2022”
> “today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study”
> “Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, p<0.00011; 20 mg=10.7%, p=0.0007†; 30 mg=6.5%, p<0.0001†, placebo=60.8%).”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

<a id="topic-3.1.2.8.3-11"></a>

##### Time to onset of primary symptom relief by 30% VAS reduction, registry results, participants with evaluable data

| Group | Participants | Median time, h (95% CI) |
| --- | --- | --- |
| Deucrictibant 10 mg | “21” | “2.0” (“1.4” to “2.4”) |
| Deucrictibant 20 mg | “16” | “3.0” (“1.9” to “4.1”) |
| Deucrictibant 30 mg | “20” | “2.9” (“1.9” to “3.9”) |
| Placebo | “51” | “23.3” (“6.1” to “NA”) |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Time to Onset of Primary Symptom Relief Assessed by a 30% Reduction in the VAS for the Primary Symptom”
> “Part I efficacy data not collected, consistent with and pre-specified in the study protocol. Includes all participants with evaluable data who completed the relevant assessment time point.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.3-12"></a>

##### Post hoc time to end of progression, deucrictibant 10, 20, and 30 mg versus placebo, 147 attacks in 62 participants

> “The EoP analysis included 147 qualifying HAE attacks treated by 62 participants with double-blinded placebo or deucrictibant IR capsule 10, 20, or 30 mg.”
> “Attacks treated with deucrictibant IR capsule (all dose groups) achieved EoP at a median time of 25-26 minutes vs 20 hours for attacks treated with placebo (Table 1 and Figure 2).”
> “Within 24 hours after treatment, 78.4%, 89.3%, and 93.5% of HAE attacks treated with deucrictibant IR capsule 10, 20, and 30 mg, respectively, achieved EoP vs 29.4% of the attacks treated with placebo (Table 1 and Figure 3).”

Source: [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9)

<a id="topic-3.1.2.8.3-13"></a>

##### Results by attack location: abdominal, peripheral, and combined attacks

> “A higher proportion of attacks primarily occurring in the abdominal area were treated with deucrictibant 10 mg than with other doses or placebo (appendix p 11).”
> “For attacks with cutaneous or abdominal manifestations, or both, shorter times to symptom relief and resolution were consistently observed with deucrictibant compared with placebo (appendix pp 13–14).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “In these post-hoc analyses, treatment VAS-3 outcomes were analysed according to attack location, i.e., abdominal (individual VAS >0 for abdominal pain), peripheral (individual VAS >0 for skin swelling and/or skin pain) or both”
> “In post-hoc analyses of treatment outcomes by attack location, deucrictibant IR capsule demonstrated consistent rapid onset of symptom relief and resolution of HAE attacks with abdominal, peripheral and combined (abdominal and peripheral) attack location”

Source: [Valerieva et al. (2023)](https://ir.pharvaris.com/static-files/6555035a-ed16-406c-a522-2eb966f73df4)

<a id="topic-3.1.2.8.3-14"></a>

##### Time from symptom onset to treatment

> “Approximately half the study-drug-treated attacks were treated within 90 min of reported onset of symptoms.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-15"></a>

##### Final analysis of 165 attacks

> “The final analysis included 165 attacks, with nine additional attacks that occurred after data cutoff for the primary analysis.”
> “Efficacy and safety results (appendix pp 16–20) were comparable to those of the primary analysis.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.3-16"></a>

##### Company characterization of efficacy across all three doses

> “In our Phase 2 placebo-controlled trial evaluating the efficacy and tolerability of deucrictibant IR capsules for the on-demand treatment of attacks in patients with HAE type 1 and 2 (RAPIDe-1), a statistically significant and clinical meaningful reduction of the patient-reported symptoms of HAE was observed for the attacks treated with all doses of deucrictibant (10, 20, 30 mg) compared to placebo-treated attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-3.1.2.8.3-17"></a>

##### Part 1 pharmacokinetics relative to EC85, 12 participants with sampling

> “Pharmacokinetics were assessed in samples collected from 12 patients during Part 1.”
> “After administration of a single dose of the immediate-release capsule formulation, mean plasma levels of deucrictibant reached the drug concentration estimated to provide 85% maximal response (EC85; above which clinical effects are anticipated based on icatibant studies)”
> “of 13·8 ng/mL within 15-30 min of drug administration and were maintained for 8 h or longer (appendix p 24).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “PHA121 was absorbed with mean plasma levels reaching the threshold of therapeutic exposure >EC85 (13.8 ng/mL) within 15-30 minutes from PHVS416 administration. Mean plasma levels of PHA121 were maintained >EC85 for approx. 8 hours at 10 mg or 20 mg doses and for >10 hours at 30 mg dose (Figure 2).”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### TSQM domain scores at 48 hours, registry results, participants with evaluable data

| Group | Participants | Effectiveness, mean (SD) | Convenience, mean (SD) | Satisfaction, mean (SD) |
| --- | --- | --- | --- | --- |
| Deucrictibant 10 mg | “21” | “79.17” (“23.179”) | “80.56” (“16.569”) | “82.50” (“18.907”) |
| Deucrictibant 20 mg | “16” | “70.45” (“30.290”) | “83.08” (“23.096”) | “80.68” (“29.702”) |
| Deucrictibant 30 mg | “20” | “72.92” (“23.085”) | “77.55” (“20.229”) | “76.74” (“22.113”) |
| Placebo | “51” | “65.38” (“23.532”) | “76.07” (“27.441”) | “64.10” (“24.623”) |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “Treatment Satisfaction Questionnaire for Medication Scores at 48 Hours Post-treatment”
> “Part I efficacy data not collected, consistent with and pre-specified in the study protocol. Includes all participants with evaluable data who completed the relevant assessment time point.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.4-2"></a>

##### TSQM reporting in the publication

> “Treatment Satisfaction Questionnaire for Medication (TSQM) score, were other lower-ranked secondary endpoints and will be reported elsewhere.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Part 1 adverse events in the attack-free state, safety analysis set of 72 participants

> “In Part 1, eight (11%) of 72 patients in the safety analysis set reported treatment-emergent adverse events within 5 days post-treatment, with two mild events of nausea and headache considered treatment-related (table 3). The most common treatment-emergent adverse events in two or more patients were headache (two [8%] of 25) and nasopharyngitis (two [8%] of 25) in the deucrictibant 30 mg group.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-2"></a>

##### Part 2 adverse events in treated attacks, safety analysis set of 156 attacks

> “In Part 2, the safety analysis set included 156 attacks treated with deucrictibant 10 mg, 20 mg, 30 mg, or placebo. No single treatment-emergent adverse event was reported by two or more patients in any treatment group. Three moderate treatment-related treatment-emergent adverse events of nausea, vomiting, and fatigue were reported in a single patient (one [5%] of 22) approximately 20 h after deucrictibant 30 mg administration for one (3%) attack with cutaneous symptoms at onset. Events resolved less than 2 h following standard treatment for nausea and vomiting. One treatment-related event of blister on fingers was reported for one (2%) of 53 placebo-treated attacks.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-3"></a>

##### Treatment-emergent adverse events within 5 days by part and dose, safety analysis set

| Event | Part 1, 10 mg (n=23) | Part 1, 20 mg (n=24) | Part 1, 30 mg (n=25) | Part 2, 10 mg (38 attacks; n'=21) | Part 2, 20 mg (29 attacks; n'=16) | Part 2, 30 mg (36 attacks; n'=22) | Part 2, placebo (53 attacks; n'=53) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Any treatment-emergent adverse event | “2 (9%)” | “2 (8%)” | “4 (16%)” | “3 (8%)”, “3 (14%)” | “1 (3%)”, “1 (6%)” | “2 (6%)”, “2 (9%)” | “3 (6%)”, “3 (6%)” |
| Any treatment-related treatment-emergent adverse event | “1 (4%)” | “1 (4%)” | “0” | “0” | “0” | “1 (3%)”, “1 (5%)” | “1 (2%)”, “1 (2%)” |

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Safety outcomes in the safety analysis set”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “Data shown are the number of attacks with an adverse event that started after the administration of the study drug and before the next administration or end of study, whichever was earlier, including only those adverse events that began within 5 days post-treatment of attack.”
> “Data shown are the number of patients with an adverse event that started after the administration of the study drug and before the next administration or end of study, whichever was earlier, including only those adverse events that began within 5 days post-treatment of attack.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-4"></a>

##### Severe, serious, and discontinuation events, laboratory, ECG, and vital signs

> “No severe (grade 3), life-threatening (grade 4), or fatal (grade 5) treatment-emergent adverse events were reported. Additionally, no treatment-emergent adverse events were reported that were serious, led to discontinuation of treatment or from the study, or were associated with changes in laboratory or ECG parameters or vital signs (table 3).”
> “No severe, serious, or treatment-limiting adverse reactions occurred in patients receiving deucrictibant. Adverse reactions were mild or moderate and resolved spontaneously or after standard treatment.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-3.1.2.8.5-5"></a>

##### Registry adverse event counts by part and treatment group

| Event group | Deaths | Serious adverse events | Other adverse events |
| --- | --- | --- | --- |
| Part I, 10 mg (participants) | “0” of “23” | “0” of “23” | “2” of “23” |
| Part I, 20 mg (participants) | “0” of “24” | “0” of “24” | “2” of “24” |
| Part I, 30 mg (participants) | “0” of “25” | “0” of “25” | “4” of “25” |
| Part II, 10 mg (study drug treated attacks) | “0” of “38” | “0” of “38” | “3” of “38” |
| Part II, 20 mg (study drug treated attacks) | “0” of “29” | “0” of “29” | “1” of “29” |
| Part II, 30 mg (study drug treated attacks) | “0” of “36” | “0” of “36” | “2” of “36” |
| “Part II Placebo” | “0” of “53” | “0” of “53” | “4” of “53” |

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

> “All AEs (including SAEs) recorded from the time of signing informed consent until the end-of-study visit. Timeframe for reporting adverse events: 5 days post-treatment.”

Source: [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211)

<a id="topic-3.1.2.8.5-6"></a>

##### Treatment-related adverse events in the top-line data and a congress poster

> “today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study”
> “PHVS416 was generally well tolerated with no treatment-related serious adverse events and no adverse events leading to treatment discontinuation. In the non-attack phase, two treatment-related adverse events were experienced by two patients; in the attack treatment phase, three treatment-related adverse events were reported for one attack treated with PHVS416 30mg (2.8%) and one treatment-related adverse event was reported for one attack treated with placebo (1.9%).”

Source: [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm)

> “PHVS416 was well-tolerated with 3 treatment-related adverse events (TRAEs) reported for 1 PHVS416 30mg-treated attack (2.8%) and 1 TRAE reported for 1 placebo-treated attack (1.9%), no serious TRAEs or AEs of severe severity, no AEs leading to treatment discontinuation, and no TRAEs of laboratory or ECG parameters, vital signs (Table 4).”
> “Table 4. Treatment-related adverse events within 48 hours after administration of study drug”
> “Presented at the 2023 American Academy of Allergy Asthma and Immunology Annual Meeting (AAAAI 2023)”

Source: [Maurer et al. (2023a)](https://ir.pharvaris.com/static-files/351671e4-35b8-4bc3-a50d-ef96e17059ab)

<a id="topic-3.1.2.8.5-7"></a>

##### Absence of injection-site reactions with oral administration

> “Antagonism of bradykinin B2 receptor was not associated with risks of serious adverse reactions in randomised controlled trials of subcutaneous icatibant nor in its use in clinical practice;”
> “the most common adverse effects were injection-site reactions, which are avoided with orally administered deucrictibant.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- The authors stated that “Limitations of the RAPIDe-1 trial include the absence of randomisation of attacks according to location and severity”; a higher proportion of attacks primarily in the abdominal area were treated with 10 mg than with other doses or placebo.
- Attacks with vomiting or involving the internal head or neck, including laryngeal attacks, were excluded from treatment, and “reoccurrence of attack symptoms following treatment was not evaluated as a predefined endpoint”.
- The population was limited to adults aged 18 to 75 years with hereditary angioedema type 1 or 2 who were not receiving long-term prophylaxis. Patients with abnormal hepatic or renal function, users of moderate or potent CYP3A4 inhibitors or inducers, and pregnant or breastfeeding women were excluded. In the mITT analysis set, 60 (97%) of 62 participants were White.
- The primary analysis was done before all enrolled participants had treated three attacks; the final analysis of 165 attacks was descriptive. The primary efficacy analysis included 62 of 74 randomized participants, with 28 to 37 attacks per deucrictibant dose. In the registry participant flow, Part II was completed by 16 of 24, 12 of 24, and 12 of 25 participants in the 10 mg, 20 mg, and 30 mg cohorts.
- The 10 mg group had no multiplicity control and was analysed descriptively. The registry notes that within-participant correlation was not accounted for in the Kaplan-Meier medians. End of progression and outcomes by attack location were post-hoc analyses.
- TSQM and other lower-ranked secondary endpoints are to be reported elsewhere. In August 2022 the FDA placed US trials on clinical hold, and only 2 remaining US participants were permitted to complete treatment of a final attack.

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext); [ClinicalTrials.gov NCT04618211 API record](https://clinicaltrials.gov/api/v2/studies/NCT04618211); [Riedl et al. (2023c)](https://ir.pharvaris.com/static-files/0bae214b-7ff8-49ec-8340-1bb60a5935b9); [Valerieva et al. (2023)](https://ir.pharvaris.com/static-files/6555035a-ed16-406c-a522-2eb966f73df4); [Pharvaris RAPIDe-1 topline press release (2022)](https://www.sec.gov/Archives/edgar/data/1830487/000156459022039123/phvs-ex991_935.htm); [Riedl et al. (2023a)](https://ir.pharvaris.com/static-files/b15c3784-03fe-4925-aada-1331942c144e)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
